Fangsheng Pharmaceutical: The company was selected for this continuation procurement, including Ezetimibe Tablets and other products.

2026-03-06 20:13:03

Fangsheng Pharmaceutical announced that on February 9, 2026, the company participated in the renewal procurement of drugs whose agreements expired in the 1st-8th batches of the national centralized procurement. According to the “Notice on the Announcement of the Selected Results for the Continuation Procurement of Drugs with Expired Agreements in the National Centralized Procurement (LC-YPJX-2026-1)” issued by the Office of the Continuation Procurement of Drugs with Expired Agreements on February 27, 2026, the company was selected for continuation procurement of the following products: Zeframib tablets, Cefixime tablets, Cefprozil tablets, Eprosartan hydrochlorothiazide tablets, Omeprazole enteric-coated tablets, and Montmorillonite powder.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes